JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis

Blood

Volumn 110, Issue 12, 2007, Pages 4030-4036

  Barosi, Giovanni ^a   Bergamaschi, Gaetano ^a   Marchetti, Monia ^a   Vannucchi, Alessandro M ^b   Guglielmelli, Paola ^b   Antonioli, Elisabetta ^a   Massa, Margherita ^a   Rosti, Vittorio ^a   Campanelli, Rita ^a   Villani, Laura ^a   Viarengo, Gianluca ^a   Gattoni, Elisabetta ^a   Gerli, Giancarla ^c   Specchia, Giorgina ^d   Tinelli, Carmine ^a   Rambaldi, Alessandro ^e   Barbui, Tiziano ^e  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Ospedale San Paolo   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT;

EID: 37049039725     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-099184     Document Type: Article

References (37)

1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737-740.
2. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol. 2005;42:248-258.
3. Barosi G, Berzuini C, Liberato LN, et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397-401.
4. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
5. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
6. Cervantes F, Pereira A, Esteve J, et al. Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
7. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96-102.
8. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73:194-198.
9. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109:2083-2088.
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
13. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
14. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108:1865-1867.
15. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131:320-328.
16. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098-2100.
17. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res. 2006;30:1457-1460.
18. Rossi D, Deambrogi C, Capello D, et al. JAK2 V617F mutation in leukaemic transformation of Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2006;135:267-268.
19. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110:375-379.
20. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;104:730-737.
21. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
22. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107:4139-4141.
23. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
24. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681-694.
25. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
26. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
27. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006;108:3548-3555.
28. Mesa RA, Powell H, Lasho T, De Wald GW, Mc-Clure R, Tefferi A. A longitudinal study of the JAK2 V617F mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. Haematologica. 2006;91:415-416.
29. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. Prepublished on March 22, 2007, as DOI 10.1182/blood-2006-12-064287. (Now available as Blood. 2007;110:840-846).
30. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631-635.
31. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847-1849.
32. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
33. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-4281.
34. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.
35. Zaleskas VM, Krause DS, Lazarides-K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PloS ONE. 2006;1:e18.
36. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236.
37. Tefferi A, Dingli D, Li C-Y, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer. 2005;104:1656-1660.